scholarly journals Parasite Carbohydrate Vaccines

Author(s):  
Jonnel A. Jaurigue ◽  
Peter H. Seeberger
2013 ◽  
Vol 20 (4) ◽  
pp. 582-589 ◽  
Author(s):  
Wei-Ji Li ◽  
Kai Long ◽  
Hong-Liang Dong ◽  
Xiao-Ming Gao

ABSTRACTPolysaccharide-encapsulated fungi are the chief source of diseases in immunocompromised hosts such as those infected with human immunodeficiency virus or neutropenia patients. Currently available polysaccharide-protein conjugate vaccines are mainly T cell dependent and are usually ineffective in weakened immune systems. In this study, laminarin, a well-characterized β-1,3-glucan, was conjugated with a prokaryotically expressed recombinant fragment (amino acids [aa] 39 to 272) of calreticulin (rCRT/39–272), which exhibits extraordinarily potent immunogenicity and adjuvanticity in experimental animals. The resultant conjugate reserves the immunostimulatory effect of rCRT/39–272 on naïve murine B cells and is capable of eliciting anti-β-glucan IgG (mostly IgG1) responses in not only BALB/c mice but also athymic nude mice. Laminarin-CRT-induced mouse antibodies (Abs) are able to bind withCandida albicansand inhibit its growthin vitro. In addition, vaccination with laminarin-CRT partially protects mice from lethalC. albicanschallenge. These results imply that rCRT/39–272 could be used as an ideal carrier or adjuvant for carbohydrate vaccines aimed at inducing or boosting IgG responses to fungal infections in immunodeficient hosts.


2012 ◽  
Vol 61 (11) ◽  
pp. 2045-2054 ◽  
Author(s):  
Lei Qiu ◽  
Xi Gong ◽  
Qianli Wang ◽  
Jie Li ◽  
Honggang Hu ◽  
...  

2013 ◽  
pp. 68-104 ◽  
Author(s):  
Benjamin Schumann ◽  
Chakkumkal Anish ◽  
Claney L. Pereira ◽  
Peter H. Seeberger

2017 ◽  
Vol 89 (10) ◽  
pp. 1403-1411 ◽  
Author(s):  
Yury E. Tsvetkov ◽  
Marina L. Gening ◽  
Ekaterina A. Kurbatova ◽  
Nelly K. Akhmatova ◽  
Nikolay E. Nifantiev

AbstractStreptococcus pneumoniae can cause many types of dangerous infectious diseases such as otitis media, pneumonia, meningitis and others that are more common in the very young and very old age. Available to date commercial vaccines based on capsular polysaccharides of S. pneumoniae of clinically important strains (first generation carbohydrate vaccines) and conjugated vaccines based on these polysaccharides (second generation carbohydrate vaccines) have certain limitations in protective efficiency. However, the efficiency of vaccines can be increased by the use of third generation vaccines based on synthetic oligosaccharide ligands representing in their structures the protective epitopes of capsular polysaccharides. The proper choice of an optimal oligosaccharide ligand is the most important step in the design of third generation carbohydrate vaccines. Herein we overview our works on the synthesis of three oligosaccharides corresponding to one, “one and a half” and two repeating units of S. pneumoniae type 14 capsular polysaccharide, immunogenic conjugates thereof and comparative immunological study of their conjugates with bovine serum albumin, which was used as a model protein carrier. The ability of obtained products to raise antibodies specific to capsular polysaccharide and homologous oligosaccharides, the induction of phagocytosis by immune antisera and active protection of immunized animals from S. pneumoniae type 14 infection were evaluated. On the basis of the results obtained tetrasaccharide comprising the repeating unit of S. pneumoniae type 14 capsular polysaccharide is an optimal carbohydrate ligand to be used as a part of the third generation carbohydrate pneumococcal vaccine.


Sign in / Sign up

Export Citation Format

Share Document